RT Journal Article
T1 Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.
A1 Williams, Dylan M
A1 Bandres-Ciga, Sara
A1 Heilbron, Karl
A1 Hinds, David
A1 Noyce, Alastair J
K1 Anticholesteremic Agents
K1 Apolipoprotein A-V
K1 Apolipoproteins B
K1 Cholesterol, LDL
AB Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid-lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence interval [CI] = 0.65, 1.07). Other target results were null, except for variants indicating Apolipoprotein-A5 or Apolipoprotein-C3 inhibition might confer protection. These findings suggest peripheral lipid variation may not have a prominent role in PD etiology, but some related drug targets could influence PD via alternate pathways. ANN NEUROL 2020;88:1043-1047.
PB John Wiley & Sons, Inc.
YR 2020
FD 2020-08-19
LK http://hdl.handle.net/10668/16149
UL http://hdl.handle.net/10668/16149
LA en
NO Williams DM, Bandres-Ciga S, Heilbron K, Hinds D, Noyce AJ; 23andMe Research Team, et al. Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization. Ann Neurol. 2020 Nov;88(5):1043-1047.
DS RISalud
RD Apr 11, 2025